Last reviewed · How we verify

NCT06112184

Digital Health Program With Participants Using an Autoinjector

Completed NA Last updated 25 May 2025
What this trial tests

NA trial testing SK-M11/3A1 Digital health program in Immune-Mediated Inflammatory Disease in 27 participants. Completed in 1 October 2024.

Timeline
10 December 2023
Primary endpoint
1 October 2024
1 October 2024

Quick facts

Lead sponsorSidekick Health
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment27
Start date10 December 2023
Primary completion1 October 2024
Estimated completion1 October 2024
Sites1 location across Iceland

Drugs / interventions tested

Conditions studied

Sponsor

Sidekick Health

Who can join

18 and older, any sex, with Immune-Mediated Inflammatory Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, single-arm, feasibility study. Up to thirty (30) participants meeting study eligibility criteria will use the SK-M11/3A1 digital health program for 12 weeks. The program will be delivered via the Sidekick mobile application (app). The study objective is to evaluate the performance and safety of the SK-M11/3A1 digital health program when added to routine medical treatment of patients with Immune-Mediated Inflammatory Disease (IMID). All participants are using a prescribed medication for regular subcutaneous injection provided in a prefilled autoinjector.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Sidekick Health trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06112184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing